EP3897585A1 - Forme posologique contenant de l'acétate d'abiratérone - Google Patents

Forme posologique contenant de l'acétate d'abiratérone

Info

Publication number
EP3897585A1
EP3897585A1 EP18827093.8A EP18827093A EP3897585A1 EP 3897585 A1 EP3897585 A1 EP 3897585A1 EP 18827093 A EP18827093 A EP 18827093A EP 3897585 A1 EP3897585 A1 EP 3897585A1
Authority
EP
European Patent Office
Prior art keywords
optionally
surfactant
binder
dosage form
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18827093.8A
Other languages
German (de)
English (en)
Inventor
Panagiotis PANAGOPOULOS
Konstantinos-Emmanouil PANITSAS
Pandora Alexaki
Dimosthenis KANTAS
George VACHRATIDIS
John VOUVALIDIS
Christina MICHALI
Charalambos PATTIHIS
Antje NORDMANN
Michalis NEOPTOLEMOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedica Ltd
Pharmaceutical Oriented Services Ltd
Original Assignee
Remedica Ltd
Pharmaceutical Oriented Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedica Ltd, Pharmaceutical Oriented Services Ltd filed Critical Remedica Ltd
Publication of EP3897585A1 publication Critical patent/EP3897585A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

La présente invention concerne une forme posologique unitaire solide pour administration orale, de préférence, un comprimé, contenant de l'acétate d'abiratérone, la forme posologique unitaire solide étant préparée par granulation par voie humide. La forme posologique unitaire solide est destinée au traitement du cancer de la prostate.
EP18827093.8A 2018-12-20 2018-12-20 Forme posologique contenant de l'acétate d'abiratérone Pending EP3897585A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2018/086401 WO2020126017A1 (fr) 2018-12-20 2018-12-20 Forme posologique contenant de l'acétate d'abiratérone

Publications (1)

Publication Number Publication Date
EP3897585A1 true EP3897585A1 (fr) 2021-10-27

Family

ID=64901558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18827093.8A Pending EP3897585A1 (fr) 2018-12-20 2018-12-20 Forme posologique contenant de l'acétate d'abiratérone

Country Status (6)

Country Link
EP (1) EP3897585A1 (fr)
AU (1) AU2018454263B2 (fr)
BR (1) BR112021017330A2 (fr)
CA (1) CA3124439A1 (fr)
SG (1) SG11202107948PA (fr)
WO (1) WO2020126017A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201207886D0 (en) 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CN103446069A (zh) 2012-05-29 2013-12-18 重庆医药工业研究院有限责任公司 一种阿比特龙的口服固体组合物及其制备方法
CN102743393A (zh) 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺
CN104069075A (zh) * 2013-03-26 2014-10-01 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙片剂及其制备方法
EP3042124A2 (fr) 2013-09-05 2016-07-13 Arçelik Anonim Sirketi Réchaud comprenant un logement de brûleur
WO2015032873A1 (fr) * 2013-09-06 2015-03-12 Synthon B.V. Compositions pharmaceutiques à charge élevée comprenant de l'acétate d'abiratérone
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
WO2015114314A1 (fr) * 2014-01-28 2015-08-06 Cipla Limited Composition pharmaceutique contenant de l'abiratérone
WO2016001208A1 (fr) 2014-06-30 2016-01-07 Galenicum Health S.L. Compositions pharmaceutiques stables sous forme de comprimés à libération immédiate
CN105596303A (zh) * 2014-11-03 2016-05-25 重庆安格龙翔医药科技有限公司 一种稳定的醋酸阿比特龙片剂及其制备方法
CZ2016573A3 (cs) * 2016-09-16 2018-03-28 Zentiva, K.S. Pevná formulace abirateronu acetátu vyráběná technologií fluidní granulace

Also Published As

Publication number Publication date
BR112021017330A2 (pt) 2021-11-09
WO2020126017A1 (fr) 2020-06-25
SG11202107948PA (en) 2021-08-30
AU2018454263B2 (en) 2024-02-15
AU2018454263A1 (en) 2022-03-03
CA3124439A1 (fr) 2020-06-25

Similar Documents

Publication Publication Date Title
JP7211644B2 (ja) ニロチニブの医薬組成物
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
US20060193910A1 (en) Tablets with improved drug substance dispersibility
KR100962447B1 (ko) 난용성 약물인 두타스테라이드의 자가유화 조성물과 이로부터 제조된 정제
JP6426293B2 (ja) 安定性が改善された錠剤形態のデュタステリド組成物
JP2004504360A (ja) １−（５−ｔｅｒｔ−ブチル−２−Ｐ−トリル−２Ｈ−ピラゾール−３−イル）−３−［４−（２−モルホリン−４−イル−エトキシ）−ナフタレン−１−イル］−ウレアの改良された経口製剤
AU2014295100B2 (en) Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.
US7115281B2 (en) Processes for the preparation of oral dosage formulations of modafinil
CA2563690C (fr) Compositions pharmaceutiques comprenant des fractions intra- et extra- granulaires
WO2019219823A1 (fr) Dispersion solide contenant du ritonavir
JP2018502130A5 (fr)
AU2016373574B2 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
EP2291079B1 (fr) Préparations pour inhibiteurs de la cathepsine k
AU2018454263B2 (en) Dosage form containing abiraterone acetate
JP5669751B2 (ja) 低い経口生物学的利用能を有する化合物のプレ圧縮崩壊性製剤
WO2022013360A1 (fr) Composition pharmaceutique comprenant un ivacaftor
US20100003319A1 (en) Raloxifene immediate release tablets
WO2012107090A1 (fr) Composition de granulés comportant du tadalafil et un délitant
EP3761965A1 (fr) Formulation de comprimé contenant du ticagrelor
US20200046695A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2023104808A1 (fr) Composition pharmaceutique comprenant de l'ibrutinib
WO2020049429A1 (fr) Nouvelle composition de lapatinib de forme galénique orale solide et procédé de fabrication
EP2363120A1 (fr) Mélange contenant du diméboline et de la mémantine

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210624

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR